FOAMIX PHARMACEUTICALS LTD's ticker is FOMX and the CUSIP is M46135105. A total of 57 filers reported holding FOAMIX PHARMACEUTICALS LTD in Q2 2018. The put-call ratio across all filers is 0.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $1,878,000 | +3.4% | 564,004 | -5.6% | 0.00% | – |
| Q3 2019 | $1,816,000 | +40.1% | 597,352 | +9.6% | 0.00% | – |
| Q2 2019 | $1,296,000 | -41.0% | 544,896 | -7.0% | 0.00% | – |
| Q1 2019 | $2,198,000 | -1.4% | 586,061 | -5.6% | 0.00% | – |
| Q4 2018 | $2,229,000 | -18.7% | 620,816 | +29.7% | 0.00% | – |
| Q3 2018 | $2,743,000 | +16.0% | 478,657 | +1.4% | 0.00% | – |
| Q2 2018 | $2,364,000 | -1.0% | 471,836 | +1.3% | 0.00% | – |
| Q1 2018 | $2,389,000 | -22.0% | 465,806 | -8.6% | 0.00% | – |
| Q4 2017 | $3,061,000 | -3.4% | 509,364 | -10.8% | 0.00% | – |
| Q3 2017 | $3,168,000 | +27.5% | 570,780 | +6.6% | 0.00% | – |
| Q2 2017 | $2,484,000 | -2.8% | 535,403 | +3.7% | 0.00% | – |
| Q1 2017 | $2,555,000 | +25450.0% | 516,145 | +32838.4% | 0.00% | – |
| Q1 2016 | $10,000 | +100.0% | 1,567 | +174.0% | 0.00% | – |
| Q4 2015 | $5,000 | +25.0% | 572 | 0.0% | 0.00% | – |
| Q3 2015 | $4,000 | -33.3% | 572 | 0.0% | 0.00% | – |
| Q2 2015 | $6,000 | – | 572 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 4,781,708 | $24,530,000,000 | 3.64% |
| Opaleye Management Inc. | 950,000 | $4,873,000 | 1.39% |
| DSC Advisors, L.P. | 1,187,604 | $6,092,000 | 1.28% |
| DAFNA Capital Management LLC | 335,500 | $1,721,000 | 0.84% |
| Vivo Capital, LLC | 855,000 | $4,386,000 | 0.62% |
| Stonepine Capital Management, LLC | 129,756 | $666,000 | 0.36% |
| Eversept Partners, LP | 107,500 | $551,475 | 0.26% |
| Tekla Capital Management LLC | 930,398 | $4,773,000 | 0.19% |
| Perceptive Advisors | 1,117,324 | $5,732,000 | 0.16% |
| Crestline Management, LP | 217,670 | $1,117,000 | 0.14% |